ZA202208339B - Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof - Google Patents

Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof

Info

Publication number
ZA202208339B
ZA202208339B ZA2022/08339A ZA202208339A ZA202208339B ZA 202208339 B ZA202208339 B ZA 202208339B ZA 2022/08339 A ZA2022/08339 A ZA 2022/08339A ZA 202208339 A ZA202208339 A ZA 202208339A ZA 202208339 B ZA202208339 B ZA 202208339B
Authority
ZA
South Africa
Prior art keywords
antibody
preparation
monoclonal antibody
method therefor
lag3 monoclonal
Prior art date
Application number
ZA2022/08339A
Other languages
English (en)
Inventor
Ge Song
Hui Xiao
Honglin He
Xu Xu
Wei-Dong Jiang
Original Assignee
Shanghai Henlius Biotech Inc
Shanghai Henlius Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biotech Inc, Shanghai Henlius Biopharmaceutical Co Ltd filed Critical Shanghai Henlius Biotech Inc
Publication of ZA202208339B publication Critical patent/ZA202208339B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2022/08339A 2020-01-21 2022-07-26 Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof ZA202208339B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010069008 2020-01-21
PCT/CN2021/072610 WO2021147837A1 (zh) 2020-01-21 2021-01-19 抗lag3单克隆抗体及其制备方法和应用

Publications (1)

Publication Number Publication Date
ZA202208339B true ZA202208339B (en) 2023-11-29

Family

ID=76993109

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/08339A ZA202208339B (en) 2020-01-21 2022-07-26 Anti-lag3 monoclonal antibody, and preparation method therefor and use thereof

Country Status (10)

Country Link
US (1) US20230074657A1 (cg-RX-API-DMAC10.html)
EP (1) EP4095159A4 (cg-RX-API-DMAC10.html)
JP (1) JP7692918B6 (cg-RX-API-DMAC10.html)
KR (1) KR20220131279A (cg-RX-API-DMAC10.html)
CN (1) CN114945595A (cg-RX-API-DMAC10.html)
AU (1) AU2021210029A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013544A2 (cg-RX-API-DMAC10.html)
CA (1) CA3165211A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021147837A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202208339B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
WO2023138677A1 (en) * 2022-01-24 2023-07-27 Crown Bioscience Inc. (Taicang) Novel anti-lag3 antibodies and derivative products
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US20190330336A1 (en) * 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
SI4339615T1 (sl) 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
UA128387C2 (uk) * 2017-04-05 2024-07-03 Ф. Хоффманн-Ля Рош Аг Антитіло до lag3
US11339218B2 (en) * 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
CN110204614B (zh) 2018-02-28 2022-07-12 广州誉衡生物科技有限公司 抗人lag-3单克隆抗体及其制备方法和用途
CN110305215B (zh) 2018-03-20 2023-11-03 基石药业 新型抗lag-3抗体多肽
CN110343179B (zh) 2018-04-02 2024-03-08 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
CN110172099B (zh) 2018-08-16 2020-03-03 上海健信生物医药科技有限公司 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途

Also Published As

Publication number Publication date
EP4095159A1 (en) 2022-11-30
EP4095159A4 (en) 2024-03-20
CA3165211A1 (en) 2021-07-29
US20230074657A1 (en) 2023-03-09
AU2021210029A1 (en) 2022-09-01
JP7692918B2 (ja) 2025-06-16
JP7692918B6 (ja) 2025-07-17
KR20220131279A (ko) 2022-09-27
JP2023510982A (ja) 2023-03-15
BR112022013544A2 (pt) 2022-09-06
WO2021147837A1 (zh) 2021-07-29
CN114945595A (zh) 2022-08-26

Similar Documents

Publication Publication Date Title
Ho et al. The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity
Ely et al. Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
Rupp et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Kwok et al. Tumour-wide RNA splicing aberrations generate actionable public neoantigens
Okamoto et al. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin
Wei et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells
Kitano et al. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
Krosl et al. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
BR112022013544A2 (pt) Anticorpo monoclonal anti-lag3 e método de preparação do mesmo e uso do mesmo
Apavaloaei et al. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer
Salvat et al. Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity
BRPI0607757A2 (pt) anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo
EP4039710A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
SG170080A1 (en) Human monoclonal antibodies to o8e
MX2024007393A (es) Complejos polipeptidicos de union a antigeno activados condicionalmente y metodos de uso de los mismos.
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
Schreiner et al. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
ZA202201464B (en) Anti-tigit antibodies and application thereof
Lee et al. Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma
Lebrec et al. Nonclinical safety assessment of engineered T cell therapies
MY189412A (en) Antibody to programmed cell death 1 (pd-1) and use thereof
Kumaresan et al. A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus
MX2024007120A (es) Complejos polipeptidicos de union a antigeno que contienen dominios extracelulares de ligandos de la superfamilia del factor de necrosis tumoral (tnfsf).